TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25731858

Group type: EXPERIMENTAL
Intervention: EPICTM nitinol vascular stent system
Number of subjects: 83
Study: 25462598

Group type: EXPERIMENTAL
Intervention: Rumination condition
Number of subjects: 59

Group type: COMPARATOR
Intervention: Distraction condition
Number of subjects: 59

Group type: COMPARATOR
Intervention: Non-dysphoric ruminating condition
Number of subjects: 59

Group type: COMPARATOR
Intervention: Non-dysphoric distracting condition
Number of subjects: 59
Study: 23757968

Group type: EXPERIMENTAL
Intervention: Tadalafil combined with behavior therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tadalafil only (control group)
Number of subjects: 60
Study: 21907861

Group type: EXPERIMENTAL
Intervention: F(E)NO group
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 220
Study: 19727663

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (dietary restrictions and exercise training)
Number of subjects: 261
Study: 16714425

Group type: EXPERIMENTAL
Intervention: 160/12.5 mg valsartan/hydrochlorothiazide (HCTZ)
Number of subjects: 1668

Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 1668

Group type: EXPERIMENTAL
Intervention: valsartan/HCTZ
Number of subjects: 1668
Study: 15492306

Group type: EXPERIMENTAL
Intervention: Standardized empirical ATP (n=313)
Number of subjects: 634

Group type: COMPARATOR
Intervention: Shock (n=321)
Number of subjects: 634
Study: 11256459

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Family therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interpersonal and social rhythm therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychoeducation, group therapy, couples therapy, family therapy, interpersonal psychotherapy
Number of subjects: 0
Study: 9365866

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 7943089

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (10 mg, 10 mg, 5 mg, 5 mg) administered in four doses at 12-hour intervals over 36 hours
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no corticosteroids)
Number of subjects: 40
Study: 2975609

Group type: EXPERIMENTAL
Intervention: Celiprolol 200-600 mg daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Chlorthalidone 12.5-37.5 mg daily
Number of subjects: 30
Study: 29695707

Group type: EXPERIMENTAL
Intervention: Orange juice consumed with 3 meals/day (WM)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Orange juice consumed in-between 3 meals/day (BM)
Number of subjects: 26
Study: 28286289

Group type: EXPERIMENTAL
Intervention: 10mg immediate release Stilnox®
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 12.5mg modified release Ambien® CR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 8mg intravenous zolpidem
Number of subjects: 0
Study: 25781379

Group type: EXPERIMENTAL
Intervention: Nursing intervention including one nurse-patient meeting before leaving the ED and two additional telephone contacts over the next 2 weeks.
Number of subjects: 265

Group type: COMPARATOR
Intervention: Control group (CG) receiving usual care without the nursing intervention.
Number of subjects: 265
Study: 23860220

Group type: EXPERIMENTAL
Intervention: Biosynthetic cellulose wound dressing (BWD) + foam (study group)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Foam dressing (control group)
Number of subjects: 46
Study: 21146937

Group type: EXPERIMENTAL
Intervention: Quetiapine (25-200mg/day) plus naltrexone (50mg/day)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo plus naltrexone (50mg/day)
Number of subjects: 62
Study: 18518938

Group type: EXPERIMENTAL
Intervention: Levamisole group (100 mg levamisole p.o. after each haemodialysis session)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo group (placebo instead of levamisole)
Number of subjects: 70
Study: 16598663

Group type: EXPERIMENTAL
Intervention: Men with offences against biological daughters or stepdaughters
Number of subjects: 291

Group type: COMPARATOR
Intervention: Men with offences against otherwise‐related or unrelated girls
Number of subjects: 291

Group type: COMPARATOR
Intervention: Men with no offences against girls
Number of subjects: 291
Study: 12687818

Group type: EXPERIMENTAL
Intervention: Enhanced Closed-loop Stimulation (ECLS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard Closed-loop Stimulation (SCLS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both ECLS and SCLS
Number of subjects: 10
Study: 10890312

Group type: EXPERIMENTAL
Intervention: 600 mg lithium carbonate for 10 days and 30 mg mirtazapine on day 9
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo capsules and 30 mg mirtazapine on day 9
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of mirtazapine and lithium
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 12
Study: 8715878

Group type: EXPERIMENTAL
Intervention: Continuing education (CE) program on stoma care
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Satisfaction survey during the course, on completion, and four months after the course
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study: 1383416

Group type: EXPERIMENTAL
Intervention: recombinant interferon treatment
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: liver biopsy
Number of subjects: 67

Group type: COMPARATOR
Intervention: conventional techniques
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: alanine aminotransferase values
Number of subjects: 67
Study: 6417728

Group type: EXPERIMENTAL
Intervention: Acetyl-salicylic acid
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no drugs)
Number of subjects: 10
Study: 31211741

Group type: EXPERIMENTAL
Intervention: Anastrozole or exemestane (5 years of adjuvant therapy)
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Haplotype analysis
Number of subjects: 883
Study: 30112584

Group type: EXPERIMENTAL
Intervention: Interventional care (up-titrated antihypertensive therapy with a single pill combination of olmesartan, amlodipine, and/or hydrochlorothiazide in 4-week intervals)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Standard care (treatment according to the 2013 European Society of Cardiology guidelines)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Interventional care
Number of subjects: 139

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 139
Study: 26946077

Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg monthly
Number of subjects: 511

Group type: COMPARATOR
Intervention: Ezetimibe 10 mg daily
Number of subjects: 511
Study: 24521173

Group type: EXPERIMENTAL
Intervention: Supervision by OMS teacher
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supervision by teaching assistant
Number of subjects: 0

Group type: COMPARATOR
Intervention: No supervision
Number of subjects: 0

Group type: COMPARATOR
Intervention: Support from simulator technician
Number of subjects: 0
Study: 19396322

Group type: EXPERIMENTAL
Intervention: PHF on-line acetate-free dialysate
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional bicarbonate dialysate
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: PHF on-line with conventional dialysate
Number of subjects: 35
Study: 15799802

Group type: EXPERIMENTAL
Intervention: Waterjet dissection
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ultrasonic aspirator
Number of subjects: 30
Study: 11524581

Group type: EXPERIMENTAL
Intervention: Laparoscopic GBP
Number of subjects: 155

Group type: COMPARATOR
Intervention: Open GBP
Number of subjects: 155
Study: 9610089

Group type: COMPARATOR
Intervention: Maternal and cord blood magnesium levels
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Cord blood magnesium levels in newborns weighing less than 3 kgs
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Cord blood magnesium levels in primiparas
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Cord blood magnesium levels in mothers aged less than 20 years
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Correlation between magnesium and zinc
Number of subjects: 52

Group type: COMPARATOR
Intervention: Comparison of magnesium levels between male and female children
Number of subjects: 52
Study: 8629744

Group type: EXPERIMENTAL
Intervention: Bupivacaine plus diclofenac (150 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lidocaine plus diclofenac (150 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 40
Study: 2899107

Group type: EXPERIMENTAL
Intervention: Alcoholic preparations (n-propanol and isopropanol)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Povidone-iodine detergent preparations
Number of subjects: 14

Group type: COMPARATOR
Intervention: Non-medicated bar soap
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Triclosan products
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-detergent
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Alcoholic formulations
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Gram-positive organisms (Staphylococcus aureus and Candida albicans)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Gram-negative bacilli (GNB) residents (Acinetobacter calcoaceticus and Enterobacter spp.)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Isolation unit handwashing/disinfection
Number of subjects: 14
Study: 12564085

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29893452

Group type: EXPERIMENTAL
Intervention: Aprepitant plus ondansetron
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus ondansetron
Number of subjects: 0
Study: 26876066

Group type: EXPERIMENTAL
Intervention: ICG-guided therapy (HD)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Empiric therapy (GE)
Number of subjects: 144
Study: 24460223

Group type: EXPERIMENTAL
Intervention: Suppress intrusive thought for one minute
Number of subjects: 1427

Group type: COMPARATOR
Intervention: Monitor intrusive thought for one minute
Number of subjects: 1427

Group type: EXPERIMENTAL
Intervention: Suppress intrusive thought effort
Number of subjects: 1427

Group type: EXPERIMENTAL
Intervention: Perceived difficulty in controlling intrusive thought
Number of subjects: 1427

Group type: EXPERIMENTAL
Intervention: Frequency of thought's recurrence
Number of subjects: 1427

Group type: EXPERIMENTAL
Intervention: Duration of thought's recurrence
Number of subjects: 1427
Study: 22399096

Group type: EXPERIMENTAL
Intervention: Combination therapy of 50 mg losartan and 12.5 mg HCTZ (n=109)
Number of subjects: 216

Group type: COMPARATOR
Intervention: High-dose therapy with 100 mg losartan (n=107)
Number of subjects: 216
Study: 21291036

Group type: EXPERIMENTAL
Intervention: Normal Pregnancy Virtual Patient program (n = 12)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Traditional clerkship (n = 11)
Number of subjects: 23
Study: 18415831

Group type: EXPERIMENTAL
Intervention: Feedback letters to physicians
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Feedback letters to pharmacists
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (physicians)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (pharmacists)
Number of subjects: 131
Study: 16188740

Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure (PEP) treatment
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: PEP treatment (repeated tests)
Number of subjects: 18
Study: 12462872

Group type: EXPERIMENTAL
Intervention: Laser treatment (Nd:YAG-laser with water spray)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (scaling alone)
Number of subjects: 27
Study: 10497848

Group type: COMPARATOR
Intervention: BHAC-DM (daunorubicin 40 mg/m2/day x 4 or more, behenoyl cytarabine 200 mg/m2/day x 10 or more, 6-mercaptopurine 70 mg/m2/day x 10 or more)
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: BHAC-EDM (daunorubicin 40 mg/m2/day x 4 or more, behenoyl cytarabine 200 mg/m2/day x 10 or more, 6-mercaptopurine 70 mg/m2/day x 10 or more, etoposide 100 mg/m2/day x 5)
Number of subjects: 655

Group type: COMPARATOR
Intervention: BHAC-DM
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: BHAC-EDM
Number of subjects: 655
Study: 8756388

Group type: EXPERIMENTAL
Intervention: Ifosfamide and etoposide (IE)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Vincristine, doxorubicin, and cyclophosphamide (VAdriaC)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Radiation therapy after the fifth chemotherapy cycle
Number of subjects: 54
Study: 2006875

Group type: EXPERIMENTAL
Intervention: Piritrexim 50 mg or more twice daily
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Piritrexim (dosages ranged from 25 to 100 mg twice a day)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Piritrexim
Number of subjects: 19
Study: 6123352

Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 3
Study: 31943529

Group type: EXPERIMENTAL
Intervention: CSP patients
Number of subjects: 291

Group type: COMPARATOR
Intervention: Control group (317 full-term pregnant women)
Number of subjects: 291
Study: 31021880

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich drink (200 ml) 2 to 3 hours before surgery
Number of subjects: 113

Group type: COMPARATOR
Intervention: Fasting from midnight (control group)
Number of subjects: 113
Study: 29704618

Group type: EXPERIMENTAL
Intervention: Couples Communication Skills Training intervention
Number of subjects: 12
Study: 27001260

Group type: EXPERIMENTAL
Intervention: Low-fat/high-carbohydrate (LFHC) meals
Number of subjects: 65

Group type: COMPARATOR
Intervention: High-fat/low-carbohydrate (HFLC) meals
Number of subjects: 65
Study: 24443305

Group type: EXPERIMENTAL
Intervention: 800 mg piracetam
Number of subjects: 18
Study: 22377561

Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 75

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 75
Study: 20665424

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation at nutritional doses
Number of subjects: 8938

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8938
Study: 17052819

Group type: EXPERIMENTAL
Intervention: Recombinant NspA vaccine (rNspA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercially available quadravalent meningococcal polysaccharide vaccine (Menomune)
Number of subjects: 0
Study: 15896427

Group type: EXPERIMENTAL
Intervention: Oxygenated water (Verum-group: n=12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal mineral water (Placebo-group: n=12)
Number of subjects: 24
Study: 11814097

Group type: EXPERIMENTAL
Intervention: PMX-F treatment (n=7)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional treatment (n=7)
Number of subjects: 40
Study: 9785065

Group type: EXPERIMENTAL
Intervention: Neuroleptanaesthesia
Number of subjects: 120

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 120

Group type: COMPARATOR
Intervention: Enflurane
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 120
Study: 7900617

Group type: EXPERIMENTAL
Intervention: Atenolol (200 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diltiazem (360 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2707929

Group type: EXPERIMENTAL
Intervention: Nesosteine (900 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 782135

Group type: EXPERIMENTAL
Intervention: Intranasal beclomethasone dipropionate (Becotide) 300 mug/day
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 30381885

Group type: EXPERIMENTAL
Intervention: Ideal standardized photographs
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Camera angulation deviation
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Camera angulation change
Number of subjects: 192
Study: 27859798

Group type: EXPERIMENTAL
Intervention: Binding communication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Persuasive communication
Number of subjects: 0
Study: 26176313

Group type: EXPERIMENTAL
Intervention: Hydration with reduced glutathione (n=262)
Number of subjects: 505

Group type: COMPARATOR
Intervention: Hydration alone (Control group, n=243)
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Subgroup analysis by percutaneous coronary intervention
Number of subjects: 505
Study: 23062791

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) - flexible morning dose (30, 50, 70 mg/day)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 21857357

Group type: EXPERIMENTAL
Intervention: EFV (efavirenz)
Number of subjects: 0
Study: 19288980

Group type: EXPERIMENTAL
Intervention: Cow's milk (CM) desensitization protocol, starting with one drop of whole CM diluted 1:25, doubled weekly for 18 weeks to achieve 200 mL intake.
Number of subjects: 13

Group type: COMPARATOR
Intervention: Soy formula (placebo)
Number of subjects: 13
Study: 16817084

Group type: EXPERIMENTAL
Intervention: Levobupivacaine (7 ml of 5 mg/ml)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control (physiologic saline solution)
Number of subjects: 74
Study: 12629559

Group type: EXPERIMENTAL
Intervention: Twice-weekly supervised strength training for 15 weeks followed by 6 months of unsupervised training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 10688075

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cefazolin (1 g)
Number of subjects: 100
Study: 9778494

Group type: EXPERIMENTAL
Intervention: Fenoterol 100 micrograms
Number of subjects: 6
Study: 8491103

Group type: EXPERIMENTAL
Intervention: Drugs that modulate sleep, such as tricyclic antidepressants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other agents affecting central nervous system neurotransmitters, particularly serotonin
Number of subjects: 0
Study: 2979224

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg b.d.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg nocte
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30714999

Group type: EXPERIMENTAL
Intervention: Below elbow cast (BEC)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Above elbow cast (AEC)
Number of subjects: 353
Study: 28051874

Group type: EXPERIMENTAL
Intervention: Heart+ App (Quantum Code Technology™)
Number of subjects: 20
Study: 26987738

Group type: EXPERIMENTAL
Intervention: Active participants managing a simulated crisis scenario (pre-test) and post-test questionnaire.
Number of subjects: 39

Group type: COMPARATOR
Intervention: Observer participants viewing the scenario via video transmission and post-test questionnaire.
Number of subjects: 39
Study: 24943088

Group type: EXPERIMENTAL
Intervention: Medical clowns (MC)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Regular group (no clowns)
Number of subjects: 91
Study: 21828378

Group type: EXPERIMENTAL
Intervention: Cediranib 20 mg plus mFOLFOX6
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Cediranib 30 mg plus mFOLFOX6
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo plus mFOLFOX6
Number of subjects: 172
Study: 19348529

Group type: EXPERIMENTAL
Intervention: High-arousing positive targets with congruent prime
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-arousing positive targets
Number of subjects: 0
Study: 17498385

Group type: COMPARATOR
Intervention: Laparoscopic high ligation of hernia sac
Number of subjects: 552
Study: 15017668

Group type: EXPERIMENTAL
Intervention: Susceptibility testing-based regimens
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard triple therapy without susceptibility testing
Number of subjects: 150
Study: 10866915

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 12

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 12
Study: 8881949

Group type: EXPERIMENTAL
Intervention: Visual laser ablation with the Ultraline side‐firing Nd:YAG laser
Number of subjects: 60

Group type: COMPARATOR
Intervention: Transurethral electroresection of the prostate (TURP)
Number of subjects: 60
Study: 1579267

Group type: EXPERIMENTAL
Intervention: 4 mg of folate daily around the time of conception
Number of subjects: 0

Group type: COMPARATOR
Intervention: Folate-free multiple vitamin
Number of subjects: 0
Study: 2870808

Group type: EXPERIMENTAL
Intervention: Acetaminophen (650 mg) and Pentazocine (25 mg)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Acetaminophen (300 mg) and Codeine (30 mg)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Acetaminophen (650 mg) and Propoxyphene Napsylate (100 mg)
Number of subjects: 129
Study: 3784917

Group type: EXPERIMENTAL
Intervention: High-dose oestrogen-progestogen therapy
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Combined oestrogen-progestogen therapy (all doses)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: All treated groups (including high-dose)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Changes in daily creatinine excretion
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 136
Study: 31688157

Group type: EXPERIMENTAL
Intervention: Ultrashort echo-time (UTE) magnetic resonance (MR) imaging
Number of subjects: 19

Group type: COMPARATOR
Intervention: Cone-beam computed tomography (CBCT)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ultrashort echo-time (UTE) magnetic resonance (MR) imaging and Cone-beam computed tomography (CBCT)
Number of subjects: 19
Study: 30204687

Group type: EXPERIMENTAL
Intervention: SGA neonates
Number of subjects: 9402

Group type: COMPARATOR
Intervention: AGA neonates
Number of subjects: 9402
Study: 28237253

Group type: EXPERIMENTAL
Intervention: Injection of plasma rich in growth factors (PRGF)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Injection of hyaluronic acid (HA)
Number of subjects: 100